GlassScriptPhysician profile
Bassel Moughrabi
NPI 1376548438
$4,182.92
in general payments reported to CMS, 2019-2025
37 companies · $875 in 2025
The $875 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $520 · 2021: $102 · 2022: $283 · 2023: $577 · 2024: $738 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091 · Education: $99.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.79 |
| Education | $99.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $649.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $504.38 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $358.28 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $321.72 | 2019-2025 | |
| Travere Therapeutics, INC. | $216.79 | 2023-2025 | Filspari |
| Amarin Pharma, INC. | $196.40 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $141.80 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $127.34 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $123.54 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.86 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $117.96 | 2019-2023 | |
| Calliditas Therapeutics US INC. | $117.08 | 2022-2025 | Tarpeyo |
| Astellas Pharma US INC | $116.91 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $114.83 | 2019-2023 | Gardasil 9 |
| Opko Pharmaceuticals, LLC | $108.66 | 2020-2023 | Rayaldee |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Moughrabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.